EMMA News and Press, Emmaus Life Sciences Incorporation From 08/05/20

--Interim Analysis Indicates Decreased Number of Diverticula and Healthy Tissue-- TORRANCE, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCPK: EMMA) , a leader in sickle cell disease treatment, announced today preliminary top-line data for two patients who mo...

TORRANCE, Calif, July 31, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA) , a leader in sickle cell disease treatment, provided today additional operational updates for the year ended December 31, 2019 as well as operational updates for the quarters ended March 31 and Jun...

TORRANCE Calif., July 29, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA) , a leader in sickle cell disease treatment, announced today that the European Medicines Agency (EMA) issued scientific advice to Emmaus regarding the clinical development pathway for Xyndari™...

DENVER, Colo., July 27, 2020- Moderna (NASDAQ:MRNA) was the weekend’s big Corona winner, as the U.S. government adjusted its existing contract, by increasing funding, by up to $472 million, for a "significantly" larger Phase 3 study of the company's COVID-19 mRNA vaccine candidate (mRNA-1...

TORRANCE, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA) , a leader in sickle cell disease treatment, announced today the opening of its regional office in Dubai. The Dubai office will be utilized to enhance Emmaus’ relationships with clinicians a...

DENVER, Colo., July 23, 2020- Yesterday’s announcement that the U.S. Department of Health and Human Services agreed to purchase up to 600 million doses of COVID-19 vaccine, from Pfizer (NYSE:PFE) and its development partner BioNTech (NASDAQ:BNTX), is the latest example of why biotech cont...

DENVER, Colo., July 16, 2020- Today’s biotech headlines include developments from Emmaus Life Sciences, Inc. (OTCQB:EMMA), AC Immune SA (NASDAQ:ACIU), and Nabriva Therapeutics plc (NASDAQ:NBRV). Emmaus Life Sciences, Inc. (OTCQB:EMMA), a leader in sickle cell disease treatment, announced ...

TORRANCE, Calif., July 16, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA) , a leader in sickle cell disease   treatment, is pleased to announce that it has engaged Partner International to lead the out-licensing activity for Emmaus’ prescription grade L-...

Emmaus Life Sciences ( OTCQB:EMMA ) to restate its previously issued financial statements for fiscal year ended December 31, 2018 and quarterly statements ended September 30, 2019. More news on: Emmaus Life Sciences, Inc., Healthcare stocks news, Read more ...

TORRANCE, Calif., July 08, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA) , a leader in sickle cell disease treatment, today announced it will be restating its previously issued audited consolidated financial statements for the twelve months ended December 31, 2018 and u...